These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 21470026

  • 21. FDA treads carefully with PrEP.
    Holmes D.
    Lancet Infect Dis; 2012 Jul; 12(7):515-6. PubMed ID: 22930826
    [No Abstract] [Full Text] [Related]

  • 22. Early experiences implementing pre-exposure prophylaxis (PrEP) for HIV prevention in San Francisco.
    Liu A, Cohen S, Follansbee S, Cohan D, Weber S, Sachdev D, Buchbinder S.
    PLoS Med; 2014 Mar; 11(3):e1001613. PubMed ID: 24595035
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Recent HIV-1 infection: to treat or not to treat, that is the question.
    Tossonian H, Conway B.
    J Infect Dis; 2012 Jan 01; 205(1):10-2. PubMed ID: 22180623
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Cost-effectiveness of nucleoside reverse transcriptase inhibitor pairs in efavirenz-based regimens for treatment-naïve adults with HIV infection in the United States.
    Brogan AJ, Talbird SE, Cohen C.
    Value Health; 2011 Jan 01; 14(5):657-64. PubMed ID: 21839403
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Boosting HIV treatment options: good news, new challenges.
    Cahn P, Sued O.
    J Infect Dis; 2013 Jul 01; 208(1):4-6. PubMed ID: 23532095
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men.
    Anderson PL, Glidden DV, Liu A, Buchbinder S, Lama JR, Guanira JV, McMahan V, Bushman LR, Casapía M, Montoya-Herrera O, Veloso VG, Mayer KH, Chariyalertsak S, Schechter M, Bekker LG, Kallás EG, Grant RM, iPrEx Study Team.
    Sci Transl Med; 2012 Sep 12; 4(151):151ra125. PubMed ID: 22972843
    [Abstract] [Full Text] [Related]

  • 36. Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients.
    Manfredi R, Calza L.
    AIDS Patient Care STDS; 2008 Apr 12; 22(4):279-90. PubMed ID: 18290748
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Abacavir/3TC vs. tenofovir/FTC: interim results from ACTG 5202.
    Albrecht H.
    AIDS Clin Care; 2008 Apr 12; 20(4):28. PubMed ID: 19271262
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.